TIDMABDX
RNS Number : 8177Z
Abingdon Health PLC
16 September 2022
Abingdon Health plc
("Abingdon" or "the Company")
Director/PDMR Dealing
York, U.K. 16 September 2022: Abingdon Health plc (AIM: ABDX), a
leading international developer and manufacturer of high quality
and effective rapid tests, announces that between 14 and 16
September 2022, Chris Yates, Chief Executive Officer and Dr
Christopher Hand, Chairman, purchased a total of 250,000 and
800,000 ordinary shares of 0.25 pence each ("Ordinary Shares")
respectively over a series of trades (the "Purchases").
The weighted average price of the shares Purchased by Dr
Christopher Hand and Chris Yates was 6.338 pence and 6.274 pence
per Ordinary Share respectively. Further to these transactions, the
interests of the two directors are as follows:
Director Previous number Number of Number of Percentage
of Ordinary Ordinary Shares Ordinary Shares of Ordinary
Shares held Purchased held following Shares held
Purchases following Purchases
Dr Christopher
Hand 12,228,467 800,000 13,028,467 10.7%
Chris Yates 7,513,844 250,000 7,763,844 6.4%
Concert Party
Further to the disclosures in the Company's Admission Document
published 11 December 2020 ("Admission Document"), both Dr
Christopher Hand and Christopher Yates are members of a concert
party (the "Concert Party"). As a result of the Purchases, the
aggregate number of Ordinary Shares held by the Concert Party has
increased from 41,811,888 to 42,861,888, representing an increase
from 34.35 per cent. to 35.21 per cent. of the issued share capital
of the Company.
The Purchases were effected under the terms of Note 11 on Rule
9.1 of the Code and therefore have no consequences under the
Takeover Code.
As set out in the Company's Admission Document, Chris Yates also
holds 392,695 options over Ordinary Shares. It was agreed with the
Panel prior to the Company's initial public offering that an
obligation under Rule 9 will not arise as a result of the issue of
new Ordinary Shares to members of the Concert Party following the
exercise of those options referred to above, without the
requirement to seek the approval of independent shareholders.
The Concert Party could therefore come to hold in aggregate up
to 43,254,513 Ordinary Shares (following the exercise of all
options held by its members only), representing a maximum potential
interest of up to 35.42 per cent. of the enlarged share capital (as
enlarged by such exercise).
Details of the transactions undertaken can be found in the
Notification of Dealing Form below.
Enquiries:
Abingdon Health plc www.abingdonhealth.com/investors/
Chris Yates, Chief Executive Officer Via Walbrook PR
Melanie Ross , Chief Financial Officer
Dr Chris Hand, Non-Executive Chairman
Singer Capital Markets (Sole Broker and Tel: +44 (0)20 7496 3000
Nominated Adviser)
Peter Steel, Alex Bond, Sam Butcher (Corporate
Finance)
Tom Salvesen (Corporate Broking)
Walbrook PR Limited Tel: +44 (0)20 7933 8780 or abingdon@walbrookpr.com
Phillip Marriage / Alice Mob: +44 (0)7867 984 082 / +44 (0)7407 804
Woodings 654
About Abingdon Health plc
Abingdon Health is a world leading developer and manufacturer of
high-quality lateral flow rapid tests across all industry sectors,
including healthcare and COVID-19. Abingdon is the partner of
choice for a growing global customer base and takes projects from
initial concept through to routine and large-scale manufacturing
and has also developed and marketed its own labelled tests.
The Company offers product development, regulatory support,
technology transfer and manufacturing services for customers
looking to develop new assays or transfer existing laboratory-based
assays to a lateral flow format. Abingdon Health aims to support
the increase in need for rapid results across many industries and
locations and produces lateral flow tests in areas such as
infectious disease, clinical testing including companion
diagnostics, animal health and environmental testing. Faster access
to results allows for rapid decision making, targeted intervention
and can support better outcomes. This ability has a significant
role to play in improving life across the world. To support this
aim Abingdon Health has also developed AppDx(R) , a customisable
image capturing technology that transforms a smartphone into a
self-sufficient, standalone lateral-flow reader.
Founded in 2008, Abingdon Health is headquartered in York,
England.
For more information visit: www.abingdonhealth.com
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it
forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018. Upon the publication of this announcement
via the Regulatory Information Service, this inside information is
now considered to be in the public domain.
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Chris Yates
------------------------------------------- ---------------------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------------
a) Position/status Chief Executive Officer
------------------------------------------- ---------------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
------------------------------------------- ---------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------------------
a) Name Abingdon Health plc
------------------------------------------- ---------------------------------------------------------------
b) LEI 213800XFI4WV3FBILO20
------------------------------------------- ---------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------------------- ---------------------------------------------------------------
c) Price(s) and volume(s)
------------------------------------------------ ----------
Price(s) Volume(s)
------------------------------------------------ ----------
5.89 pence 50,933
------------------------------------------------------------------------------------------------- ----------
5.9499 pence 50,000
------------------------------------------------------------------------------------------------- ----------
6.35 pence 10,000
------------------------------------------------------------------------------------------------- ----------
6.375 pence 25,000
------------------------------------------------------------------------------------------------- ----------
6.35 pence 40,000
------------------------------------------------------------------------------------------------- ----------
6.4 pence 24,067
------------------------------------------------------------------------------------------------- ----------
6.8 pence 50,000
------------------------------------------------------------------------------------------------- ----------
d) Aggregated information Total volume: 250,000 Ordinary
Shares
Volume weighted average price:
6.274 pence per Ordinary Share
e) Date of the transaction 14 September 2022, other than purchases
referred to in 4 c) of:
i) 40,000 Ordinary Shares and 24,067
Ordinary Shares on 15 September 2022;
and
ii) 50,000 Ordinary Shares on 16 September
2022
------------------------------------------- ---------------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
------------------------------------------- ---------------------------------------------------------------
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr Christopher Hand
--------------------------- -------------------------------------------------------------------------------
2 Reason for the notification
------------------------------------------------------------------------------------------------------------
a) Position/status Chairman
--------------------------- -------------------------------------------------------------------------------
b) Initial notification Initial Notification
/Amendment
--------------------------- -------------------------------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
------------------------------------------------------------------------------------------------------------
a) Name Abingdon Health plc
--------------------------- -------------------------------------------------------------------------------
b) LEI 213800XFI4WV3FBILO20
--------------------------- -------------------------------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
------------------------------------------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.025 pence each
financial instrument,
type of instrument
Identification code GB00BLF79J41
b) Nature of the transaction Purchase of Ordinary Shares
--------------------------- -------------------------------------------------------------------------------
c) Price(s) and volume(s)
----------- ---------------------------------------------------------------
Price(s) Volume(s)
----------- ---------------------------------------------------------------
6 pence 500,000
-------------------------------------------- ---------------------------------------------------------------
6.9 pence 300,000
-------------------------------------------- ---------------------------------------------------------------
d) Aggregated information Total volume: 800,000 Ordinary Shares
Volume weighted average price: 6.338 pence per Ordinary Share
e) Date of the transaction 500,000 Ordinary Shares were purchased on
14 September 2022 and 300,000 Ordinary Shares
were purchased on 16 September 2022.
--------------------------- -------------------------------------------------------------------------------
f) Place of the transaction London Stock Exchange, AIM
--------------------------- -------------------------------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHEQLFFLKLFBBV
(END) Dow Jones Newswires
September 16, 2022 11:19 ET (15:19 GMT)
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Abingdon Health (LSE:ABDX)
Historical Stock Chart
From Apr 2023 to Apr 2024
